PetCanCure®
PetCanCure®is applied to monitoring cancer recurrence and risk evaluation for post-op cancer dogs. By monitoring the variation of cancer genome in cell-free DNA (cfDNA) of post-op cancer dogs continually, equipping with big data and artificial intelligence, it evaluates cancer recurrence index (CRI).

Product parameters
Scope of application: Dogs with cancer who have undergone radical surgery
Test indicators: Cancer Recurrence Index, CRI
Sample requirements: 4ml of peripheral whole blood (non coagulation and hemolysis required)
Detection cycle: 10 working days
Detection significance: Significance of detection: The risk of cancer recurrence is monitored continuously and dynamically through postoperative blood, which realizes individualized postoperative management of dogs with cancer, and provides important clinical reference information for postoperative adjuvant treatment decision-making

Contact
📍 11F, Building 2, DBH Life Sciences & Health Industrial Park 2028 Shenyan Road Yantian, Shenzhen, Guangdong 518000 China
深圳特趣生物科技有限公司
Copyright 2022
粤公网安备 44030802000618号